Late-Phase Research for Pharma and Biotechs

We help you plan early for long-term commercial success, helping you to mitigate risk and establish evidence. 
Benefits
01

Establish value early on

Generate evidence to tell a compelling value story about the safety and effectiveness of your treatment.
02

Accelerate post-marketing activities

Build knowledge and gather evidence early for new indications, scientific differentiation and product positioning.
03

Generate evidence of long-term safety and effectiveness

Satisfy regulatory requirements to prove your product is safe and that benefits of treatment outweigh the risks.

With accelerated approvals and regulatory focus on risk management and mitigation strategies, the need has never been greater for healthcare companies to be diligent when it comes to late-phase or peri-approval research.

Kantar has more than 30 years of clinical research experience and can design a customised study to meet the needs of your product or research area. Our solutions enable you to adhere to risk management requirements, establish evidence for safety issues, and assess health outcomes and economics in various settings.

Featured solutions
Get comprehensive research and data to evaluate patient outcomes, treatment patterns, resource utilisation and costs.
Accurate and holistic analysis on the incidence, distribution, and control of diseases and factors relating to health.
Save time and improve evidence generation with linked clinical and patient-reported data.